Ambys Medicines
Nenad Grmusa leads the R&D Strategy and External Innovation (RSEI) group at Takeda. In this role, he oversees all external research and development activities including strategic venture investments, academic alliances, R&D collaborations, and spinouts. He is also responsible for R&D Finance and Portfolio Strategy, innovative R&D business, and venture investment models, and divestiture strategies for non-core assets.
Previously, Mr. Grmusa served as Head of the Center for External Innovation (CEI) and R&D Portfolio & Investment Strategy at Takeda, where he supported the Head of R&D in managing Takeda’s diverse pipeline from early discovery to commercial life cycle management. Mr. Grmusa has 20 years of experience in R&D finance, financial planning and analysis, and pharmaceutical portfolio management.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.